Extended release immunomodulatory implant to facilitate bone morphogenesis

Patent metadata

Field	Value
Publication number	US-2020315800-A1
Application number	US-201916377314-A
Country	US
Kind code	A1
Filing date	Apr 8, 2019
Priority date	Apr 8, 2019
Publication date	Oct 8, 2020
Grant date	—

Abstract

An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including one or more interleukins, and an outer portion including an immunomodulatory stimulant such as an antigen.

First claim

What is claimed is:

1 . An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, comprising:
an inner portion including one or more interleukins; and, an outer portion including an antigen operatively arranged to activate an innate immune system.

2 . The implant as recited in claim 1 , wherein the implant comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

3 . The implant as recited in claim 2 , wherein the implant consists of inert beta-tricalcium phosphate, calcium carbonate, silicon, and polylactic-co-glycolic acid, wherein the silicon is 1% by weight.

4 . The implant as recited in claim 1 , wherein the inner portion comprises at least one of interleukin 4, interleukin 10, and interleukin 13.

5 . The implant as recited in claim 1 , wherein the antigen comprises at least one of lipopolysaccharide and lipoteichoic acid.

6 . The implant as recited in claim 5 , wherein the antigen consists of a mixture of:
50% by weight lipopolysaccharide; and, 50% by weight lipoteichoic acid.

7 . The implant as recited in claim 5 , wherein the antigen consists of 100% by weight lipopolysaccharide.

8 . The implant as recited in claim 5 , wherein the antigen consists of 100% by weight lipoteichoic acid.

9 . The implant as recited in claim 5 , wherein the lipopolysaccharide is derived from Escherichia coli.

10 . The implant as recited in claim 5 , wherein the lipoteichoic acid is derived from Staphylococcus aureus.

11 . The implant as recited in claim 1 , wherein the inner portion comprises a first density and the outer portion comprises a second density, the first density being greater than the second density.

12 . The implant as recited in claim 1 , wherein the inner portion comprises a first porosity and the outer portion comprises a second porosity, the second porosity being greater than the first porosity.

13 . The implant as recited in claim 12 , wherein the first porosity and the second porosity are connected by one or more channels.

14 . The implant as recited in claim 1 , wherein the inner portion comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite, impregnated with the one or more interleukins.

15 . The implant as recited in claim 1 , wherein the outer portion comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite, impregnated with the antigen.

16 . The implant as recited in claim 1 , wherein the outer portion consists of the antigen.

17 . The implant as recited in claim 1 , wherein the inner portion comprises:
an innermost portion including interleukin 10 and interleukin 13; and, an inner layer including interleukin 4.

18 . The implant as recited in claim 1 , wherein:
the inner portion comprises hydroxyapatite; and, the outer portion comprises:
an inner layer including beta-tricalcium phosphate including one or more interleukins; and,
an outer layer including at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma.

19 . The implant as recited in claim 1 , wherein the implant comprises at least one of allograft bone, autograft bone, xenograft bone, a titanium implant, a polyether ether ketone (PEEK) implant, and synthetic bone void filler.

20 . An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, comprising:
an implant matrix including a first material, the implant matrix including:
an inner portion including at least one of interleukin 4, interleukin 10, and interleukin 13; and,
an outer portion including at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma.

21 . The implant as recited in claim 20 , wherein the first material comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

22 . The implant as recited in claim 21 , wherein the first material consists of inert beta-tricalcium phosphate, calcium carbonate, silicon, and polylactic-co-glycolic acid, wherein the silicon is 1% by weight.

23 . The implant as recited in claim 21 , wherein the outer portion consists of a mixture of:
50% by weight lipopolysaccharide; and, 50% by weight lipoteichoic acid.

24 . The implant as recited in claim 21 , wherein the outer portion consists of:
100% by weight lipopolysaccharide; or, 100% by weight lipoteichoic acid.

25 . The implant as recited in claim 21 , wherein the inner portion is impregnated with the at least one of interleukin 4, interleukin 10, and interleukin 13.

26 . The implant as recited in claim 21 , wherein the outer portion is impregnated with the at least one of lipopolysaccharide and lipoteichoic acid.

27 . The implant as recited in claim 20 , wherein the first material comprises at least one of allograft bone, autograft bone, xenograft bone, a titanium implant, a polyether ether ketone (PEEK) implant, and synthetic bone void filler.

28 . A method of manufacturing an extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, the method comprising:
forming an inner portion of the implant of a first material; applying at least one of interleukin 4, interleukin 10, and interleukin 13 to the inner portion; forming an outer portion of the implant of a second material, the outer portion enclosing the inner portion; and, applying at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma to the outer portion.

29 . The method as recited in claim 28 , wherein:
the first material comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite; and, the second material comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

30 . The method as recited in claim 28 , wherein the step of applying the at least one of interleukin 4, interleukin 10, and interleukin 13 to the inner portion comprises:
impregnating the inner portion with the at least one of interleukin 4, interleukin 10, and interleukin 13.

31 . The method as recited in claim 29 , wherein the step of applying the at least one of interleukin 4, interleukin 10, and interleukin 13 to the inner portion comprises:
creating a substance comprising the at least one of interleukin 4, interleukin 10, and interleukin 13; and, applying the substance to the first material.

32 . The method as recited in claim 28 , wherein the step of applying the at least one of lipopolysaccharide and lipoteichoic acid to the outer portion to the outer portion comprises:
impregnating the outer portion with the at least one of lipopolysaccharide and lipoteichoic acid.

33 . The method as recited in claim 29 , wherein the step of applying the at least one of lipopolysaccharide and lipoteichoic acid to the outer portion to the outer portion comprises:
creating a mixture consisting of 50% by weight lipopolysaccharide and 50% by weight lipoteichoic acid; and, applying the mixtur

Assignees

• Suddaby Loubert S

Inventors

• Suddaby Loubert S

Classifications

• A61K31/739

  Lipopolysaccharides · CPC title

• A61F2002/30235

  tubular, e.g. sleeves · CPC title

• A61F2002/30985

  using three dimensional printing [3DP] · CPC title

• A61F2002/30011

  differing in porosity · CPC title

• A61F2002/30014

  differing in elasticity, stiffness or compressibility · CPC title